AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03708146
Drug: BIA 5-1058
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg and 100 mg tablets; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), BIA 5-1058 will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), BIA 5-1058 will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water.
Trial: NCT03708146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), placebo will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), placebo will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water.
Trial: NCT03461042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule once daily before bedtime for 12 weeks since informed consent
Trial: NCT03772223
Drug: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).
Trial: NCT03772223
Drug: Treatment C (Albuterol Sulfate metered dose inhaler)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
Trial: NCT00002784
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
Trial: NCT00676884
Drug: Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mgs s.c. b.i.d.
Trial: NCT00676884
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mL s.c. b.i.d.
Trial: NCT00002784
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
Trial: NCT00002784
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
Trial: NCT00002784
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
Trial: NCT00002784
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
Trial: NCT03743922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule
Trial: NCT00350961
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00232141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02882087
Drug: Placebo plus MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
Trial: NCT01188317
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: repeated daily doses
Trial: NCT03918135
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg of ibuprofen(intrafen 400mg/4ml Gen ilaç sanayi, Turkey) intravenous (IV) was given 100 patients~Other Names:~Dorifen
Trial: NCT01088256
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
Trial: NCT00849056
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo weekly subcutaneous injection
Trial: NCT04415268
Drug: CFTR Modulators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care: Lumacaftor with Ivacaftor or Tezacaftor combined with Ivacaftor.~For children between 6 and 11 years of age, Lumacaftor 400 mg combined with Ivacaftor 500 mg in total per day, divided into 2 doses per day; for those over 11 years of age, Tezacaftor 100 mg combined with Ivacaftor 150 mg in the morning, adding a dose of Ivacaftor 150 mg at night.~https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000833-37/ES
Trial: NCT00051974
Drug: VELCADE™ (bortezomib) for Injection (formerly PS-341)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02181699
Drug: KHK2823
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single agent KHK2823
Trial: NCT04006860
Drug: SHC014748M Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHC014748M Capsules: 200mg
Trial: NCT01368081
Drug: Placebo (low dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily
Trial: NCT01368081
Drug: Placebo (high dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily
Trial: NCT01088256
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients get one pill of placebo (sugar-pill) per day for 8 days.
Trial: NCT02098278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01351753
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills and capsules for metformin, orlistat and topiramate
Trial: NCT03456531
Drug: NSAIDs ibubrofen,Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical treatment as NSAIDs ibubrofen,Aspirin
Trial: NCT01829399
Drug: Bupivacaine with Epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-15 mL 0.25% Bupivicaine with epinephrine 1:200,000 subcutaneous axillary ring
Trial: NCT01829399
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02729623
Drug: Kite Systems cannaHALER cannabis Inhaler.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02750150
Drug: Fresh-frozen plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00359151
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.
Trial: NCT00359151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
Trial: NCT01710631
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03034382
Drug: Lidocaine Hydrochloride 1% and epinephrine 1:400,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
Trial: NCT00058006
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02749630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to UTTR1147A administered intravenously
Trial: NCT00836069
Drug: No drug name provided by Sponsor; drug referenced as PD 0332334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental study drug for generalized anxiety disorder, oral tablet, at a total daily dose of 450mg or 600mg, twice daily for 8 weeks and then 2 weeks of dose tapering.
Trial: NCT00836069
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive substance, oral tablet, once per day, for 10 weeks.
Trial: NCT02214433
Drug: Placebo IV Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sterile IV solution of 5% dextrose in water
Trial: NCT02214433
Drug: Placebo Tablet or Capsule
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
Trial: NCT03739411
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo chemotherapy for cancer outside of this study.
Trial: NCT02647320
Drug: DS-8500a 25mg
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8500a 25mg tablet for oral administration
Trial: NCT02647320
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching DS-8500a tablet for oral administration
Trial: NCT02647320
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching sitagliptin over-capsule for oral administration
Trial: NCT02049151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
Trial: NCT02049151
Drug: Cyclophosphamide (CPA)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m\^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.
Trial: NCT03057977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT04591444
Drug: Glass Ionomer Sealant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following the manufacturer's recommendations, prophylaxis and prior drying of the treated surface was carried out, the product was also dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush and light-cured for 20 s.
Trial: NCT00681746
Drug: AZD6280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.
Trial: NCT00247585
Drug: Ethanol (Bourbon or Vodka)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02552641
Drug: Clarythromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03236233
Drug: PC786 - Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of single doses
Trial: NCT03236233
Drug: Placebo - Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of single doses
Trial: NCT01999725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules or matching suspension
Trial: NCT01718444
Drug: Progestin
RxNorm normalized name: Progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01488201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03236233
Drug: Placebo - Repeat doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of repeat doses
Trial: NCT04549051
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
Trial: NCT01488201
Drug: KHK4827
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00946192
Drug: Transdermal 17Beta-estradiol, progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
Trial: NCT00946192
Drug: Ethinyl Estradiol + Desogestrel
RxNorm normalized name: desogestrel / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
Trial: NCT00379067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03662516
Drug: Ethinyl estradiol (EE) and levonorgestrel (LN)
RxNorm normalized name: estradiol / ethinyl estradiol / levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
Trial: NCT00815893
Drug: Normal Saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Normal Saline 0.25ml/kg infusion for 10minues
Trial: NCT02095704
Drug: paracetamol oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
Trial: NCT02831517
Drug: BIIB074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT02831517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo
Trial: NCT01353638
Drug: Dipeptiven (Alanyl-glutamine-dipeptide)
RxNorm normalized name: palmitoyl dipeptide-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
Trial: NCT06613919
Drug: Anti-Tuberculosis Treatment
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard, weight adjusted anti-TB therapy for six months
Trial: NCT06613919
Drug: Anti-Tuberculosis Treatment
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard, weight-adjusted anti-TB therapy for nine months
Trial: NCT00708097
Drug: NaF
RxNorm normalized name: Renaf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride
Trial: NCT00708097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03250325
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
Trial: NCT03549026
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg
Trial: NCT02337764
Drug: TVP-1012 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVP-1012 1mg Tablets
Trial: NCT01636843
Drug: NNC0109-0012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin), once weekly.
Trial: NCT01636843
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin), once weekly.
Trial: NCT00964704
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle
Trial: NCT01345669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT00141128
Drug: SS-RBX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03145948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is administered orally.
Trial: NCT04478448
Drug: Flupirava
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet contains 200 mg Favipiravir
Trial: NCT02191813
Drug: Seresis®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02191813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00532623
Drug: Sequential
RxNorm normalized name: TABLET, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles.
Trial: NCT03928366
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil
Trial: NCT00206713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered SC once daily during the randomized retreatment phase.
Trial: NCT03595397
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour.
Trial: NCT04375514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calculated volume to match active treatment by inhalation of nebulized solution
Trial: NCT00715208
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00412113
Drug: Amlodipine besylate/atorvastatin calcium single pill combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/atorvastatin single pill combination 10/20 mg
Trial: NCT00412113
Drug: Amlodipine besylate/atorvastatin calcium single pill combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/atorvastatin single pill combination 5/20 mg
Trial: NCT00715208
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00526175
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2, i.v., day 22.
Trial: NCT00526175
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Age \<1 year 1-2 years 2-3 years \> 3 years MTX 5 mg 8 mg 10 mg 12 mg
Trial: NCT01755728
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
Trial: NCT06712381
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carac (fluorouracil) Cream, 0.5% is used by adults to treat skin conditions on the face and front part of the scalp called solar keratosis or actinic keratosis.
Trial: NCT01359501
Drug: Chinese medical treatment-LCH1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start to take the powder of Chinese herb-LCH1 3g\*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.